admin, Author at PsyNews.com

Home Authors Posts by admin

397 POSTS 0 COMMENTS

https://psynews.com

Psychedelic Bulletin: Microdosing Study Causes a Stir; COMPASS Secures 5th US...

Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Numinus Announces Departure of Stacey Wallin

PTSF86 – Ayahuasca, Chronic Pain, and Legal Psilocybin, with Payton Nyquvest...

Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured...

Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs

PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat...

Psychedelic and Mysticism: The Debate Continues

PT274 – Juan Pablo Cappello – Nue Life: Using Digital Phenotyping...

Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital...

12 3...40 Page 1 of 40

EDITOR PICKS

Psychedelic Bulletin: Microdosing Study Causes a Stir; COMPASS Secures 5th US...

Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Numinus Announces Departure of Stacey Wallin

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

PTSF49 – MDMA For Alcoholism, The Placebo Effect, and Ceremonial Magicians

Psychedelic Bulletin: Field Trip Raising $83m; NYU Langone Launches Psychedelic Medicine...

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin

Psychedelic Bulletin: Microdosing Study Causes a Stir; COMPASS Secures 5th US...

Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Numinus Announces Departure of Stacey Wallin

PTSF86 – Ayahuasca, Chronic Pain, and Legal Psilocybin, with Payton Nyquvest...

Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured...

Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs

PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat...

Psychedelic and Mysticism: The Debate Continues

PT274 – Juan Pablo Cappello – Nue Life: Using Digital Phenotyping...

Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital...

EDITOR PICKS

Psychedelic Bulletin: Microdosing Study Causes a Stir; COMPASS Secures 5th US...

Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Numinus Announces Departure of Stacey Wallin

POPULAR POSTS

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

PTSF49 – MDMA For Alcoholism, The Placebo Effect, and Ceremonial Magicians

Psychedelic Bulletin: Field Trip Raising $83m; NYU Langone Launches Psychedelic Medicine...

POPULAR CATEGORY